Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Safety and Efficacy of PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3)
Sponsor: Pegavision Corporation
Summary
The goal of this clinical trial is to learn if PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3) are safe and effective for vision correction in adults. It will also assess the comfort and overall experience of wearing these lenses. The main questions it aims to answer are: Do PEGAVISION G3 lenses provide vision correction comparable to CooperVision Clariti 1 day contact lenses? What medical problems or discomfort do participants experience when using PEGAVISION G3 lenses? Researchers will compare PEGAVISION G3 lenses to CooperVision Clariti 1 day contact lenses to determine if they are a safe and effective option for daily vision correction.
Official title: A Multicenter, Randomized, Double-blind, Parallel, Controlled Study Assessing the Safety and Efficacy of PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2025-01-21
Completion Date
2025-08-14
Last Updated
2026-08-20
Healthy Volunteers
No
Conditions
Interventions
Experimental Intervention
Name: PEGAVISION G3 Silicone Hydrogel Daily Disposable Soft Contact Lenses Type: Medical Device (Investigational) Description: Participants in this arm will wear PEGAVISION G3 daily disposable silicone hydrogel soft contact lenses for three months to evaluate their safety, efficacy, and comfort compared to the control group.
Active Comparator Intervention
Name: CooperVision Clariti 1 day Soft Contact Lenses Type: Medical Device (Approved Comparator) Description: Participants in this arm will wear Clariti 1 day daily disposable soft contact lenses, serving as the control group for comparison with PEGAVISION G3 lenses. Both interventions involve daily wear for at least 8 hours per day, 5 days per week, over a 3-month period, with periodic assessments of visual acuity, safety, and comfort.